Patient Characteristics
| Characteristic | Parameter | Overall | Non-SNB, n = 1,168 (69.5%) | ICG SNB, n = 161 (9.6%) | P, non-SNB vs. ICG SNB | Hybrid SNB, n = 351 (20.9%) | P, non-SNB vs. hybrid SNB | P, ICG SNB vs. hybrid SNB |
|---|---|---|---|---|---|---|---|---|
| PSA before treatment (ng/mL) | Median | 9.5 | 9.7 | 9.4 | 0.6 | 9 | 0.002 | 0.1 |
| IQR | 6.8–16 | 6.9–16 | 6.7–18 | 6.4–14 | ||||
| Age (y) | Median | 65 | 65 | 67 | <0.001 | 65 | 0.1 | <0.001 |
| IQR | 60–69 | 60–68 | 64–71 | 60.5–69 | ||||
| Briganti LNI risk* | Median | 12.6 | 11.9 | 20.5 | <0.001 | 12.4 | 0.4 | <0.001 |
| IQR | 6.1–30.5 | 5.6–29.1 | 10.9–41.7 | 6.2–29.2 | ||||
| Biopsy GS | 6 | 212 (12.6) | 187 (16) | 7 (4.3) | <0.001 | 18 (5.1) | <0.001 | 0.03 |
| 7 | 954 (56.8) | 638 (54.6) | 87 (54) | 229 (65.2) | ||||
| 8–10 | 514 (30.6) | 343 (29.4) | 67 (41.6) | 104 (29.6) | ||||
| cT | cT1c | 250 (14.9) | 180 (15.4) | 18 (11.2) | 0.3 | 52 (14.8) | 0.8 | 0.5 |
| cT2 | 941 (56) | 655 (56.1) | 94 (58.4) | 192 (54.7) | ||||
| ≥cT3 | 489 (29.1) | 333 (28.5) | 49 (30.4) | 107 (30.5) | ||||
| Percentage of positive cores | <33% | 454 (27) | 319 (27.3) | 23 (14.3) | <0.001 | 112 (31.9) | 0.2 | <0.001 |
| 33%–66% | 711 (42.3) | 504 (43.2) | 67 (41.6) | 140 (39.9) | ||||
| >66% | 515 (30.7) | 345 (29.5) | 71 (44.1) | 99 (28.2) | ||||
| cN | cNx | 387 (23) | 323 (27.7) | 3 (1.9) | <0.001 | 61 (17.4) | <0.001 | <0.001 |
| cN0 | 1198 (71.3) | 778 (66.6) | 133 (82.6) | 287 (81.8) | ||||
| cN1 | 95 (5.7) | 67 (5.7) | 25 (15.5) | 3 (0.9) | ||||
| Follow-up (mo) | Median | 38 | 46.5 | 15 | <0.001 | 35 | <0.001 | <0.001 |
| IQR | 14–66 | 17–70 | 7–25 | 14–58 | ||||
| Operative time (min) | Median | 119 | 115 | 111 | 0.01 | 121 | <0.001 | <0.001 |
| IQR | 100–126 | 99–128 | 97–121 | 113.5–131 | ||||
| LNs removed | Median | 12 | 11 | 20 | <0.001 | 17 | <0.001 | <0.001 |
| IQR | 8–18 | 6–15 | 17–25 | 11–21 | ||||
| pN stage | pN0 | 1 302 (77.5) | 947 (81.1) | 103 (64) | <0.001 | 252 (71.8) | <0.001 | <0.001 |
| pN1 | 378 (22.5) | 221 (18.9) | 58 (36) | 99 (28.2) | ||||
| Pathologic GS | 6 | 158 (9.4) | 129 (11) | 3 (1.9) | <0.001 | 26 (7.4) | 0.1 | <0.001 |
| 7 | 1 116 (66.4) | 754 (64.6) | 131 (81.4) | 231 (65.8) | ||||
| 8–10 | 406 (24.2) | 285 (24.4) | 27 (16.8) | 94 (26.8) | ||||
| pT stage | ≤pT2c | 851 (50.7) | 593 (50.8) | 55 (34.2) | <0.001 | 203 (57.8) | 0.005 | <0.001 |
| pT3a | 411 (24.5) | 260 (22.3) | 68 (42.2) | 83 (23.6) | ||||
| ≥pT3b | 418 (24.9) | 315 (27) | 38 (23.6) | 65 (18.5) | ||||
| Positive nodes | >2 | 121 (7.2) | 68 (5.8) | 19 (11.8) | <0.001 | 34 (9.7) | <0.001 | 0.1 |
| 0 | 1 302 (77.5) | 948 (81.2) | 102 (63.4) | 252 (71.8) | ||||
| 1–2 | 257 (15.3) | 152 (13) | 40 (24.8) | 65 (18.5) | ||||
| Surgical margins | Negative | 1 054 (62.7) | 712 (61) | 102 (63.4) | 0.6 | 240 (68.4) | 0.01 | 0.3 |
| Positive | 626 (37.3) | 456 (39) | 59 (36.6) | 111 (31.6) | ||||
| Salvage radiotherapy | No | 1 232 (73.3) | 843 (72.2) | 133 (82.6) | 0.006 | 256 (72.9) | 0.8 | 0.02 |
| Yes | 448 (26.7) | 325 (27.8) | 28 (17.4) | 95 (27.1) |
↵* According to nomogram of Briganti et al. (11).
PSA = prostate-specific antigen; IQR = interquartile range; GS = Gleason score; LN = lymph nodes.
Qualitative data are number followed by percentage in parentheses.